Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy
Study sponsor: Kura Oncology, Inc. · KURA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-05-02Actual
Enrollment · participants296Actual
Source updated2024-06-21Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.